The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 adaptive dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of ADCT-402 in patients with relapsed or refractory B-cell lineage non Hodgkin lymphoma (B-NHL).
 
Ki Y. Chung
Consulting or Advisory Role - Genentech; Sanofi
Speakers' Bureau - Genentech; Sanofi
Research Funding - MedImmune (Inst)
 
Mehdi Hamadani
Honoraria - Celgene
Consulting or Advisory Role - Celerant; MedImmune
Research Funding - Takeda
 
Brad S. Kahl
Consulting or Advisory Role - Cell Therapeutics; Millennium; Seagen
Research Funding - Roche/Genentech (Inst)
 
Leonard T. Heffner
Consulting or Advisory Role - Pfizer
Research Funding - Abbvie; Amgen; Biotest; Idera; Onyx; Pfizer
 
Paolo Fabrizio Caimi
Stock and Other Ownership Interests - Gilead Sciences; Incyte; Pharmacyclics; Seagen
Speakers' Bureau - Spectrum Pharmaceuticals
Travel, Accommodations, Expenses - TRACON Pharma
 
Jay Marshall Feingold
Employment - ADC Therapeutics; Daiichi Sankyo
 
Owen A. O'Connor
Honoraria - Millennium; Mundipharma; Novartis; Seagen
Consulting or Advisory Role - Allos Therapeutics; Millennium; Mundipharma; Novartis; Seagen; Spectrum Pharmaceuticals
Research Funding - Acetylon Pharmaceuticals; Celgene; Millennium; Roche; Seagen; Spectrum Pharmaceuticals
Travel, Accommodations, Expenses - Acetylon Pharmaceuticals; Millennium; Mundipharma; Seagen; Spectrum Pharmaceuticals